2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2827

A Novel Statistical Method to Resolve Cellular Heterogeneity in Disease Tissues: Integrating Transcriptomic Data in Accelerating Medicines Partnership (AMP) – RA Network Phase 1 Data
Abstract Number: 1917

A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Abstract Number: 2018

A Novel Ultrasound Scoring System for the Pediatric Knee
Abstract Number: 681

A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts
Abstract Number: 1331

A Pathogenic Role of Porphyomonas Gingivalis Fimbriae (FimA) in Periodontitis-Associated Rheumatoid Arthritis
Abstract Number: 781

A Patient Based Reliability Exercise of Omeract Ultrasound Definitions in Giant Cell Arteritis
Abstract Number: 1902

A Pattern of Higher Serum Levels of IL-10 and MMP-3, Along with Lower IL-6R, Identify RA Patients with Interstitial Lung Disease
Abstract Number: 1022

A Personalized Medicine Approach to Improve the Prediction of Azathioprine-Induced Pancreatic Injury: Preliminary Results
Abstract Number: 2072

A Pharmacokinetic and Pharmacodynamic Evaluation of URC102, a Potent and Selective Inhibitor of URAT1, after Single and Multiple Oral Administrations in Healthy Volunteers
Abstract Number: 2884

A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 7L

A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
Abstract Number: 15L

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee
Abstract Number: 1202

A Phase 2A, Placebo-Controlled, Randomized Study of ABT-981, an Anti-Interleukin-1Alpha and -1Beta Dual Variable Domain Immunoglobulin, to Treat Erosive Hand Osteoarthritis
Abstract Number: 1904

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Upadacitinib (ABT-494), a Selective JAK-1 Inhibitor, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Dmards
Abstract Number: 2441

A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Similarities between LBEC0101 and Etanercept Reference Product in Terms of Efficacy and Safety in Patients with Active Rheumatoid Arthritis Inadequately Responding to Methotrexate

« Previous Page
1
…
3
4
5
6
7
…
201
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].